Abstract
Beta adrenergic receptors (βARs) are G-protein-coupled receptors essential for physiological responses to the hormones/neurotransmitters epinephrine and norepinephrine which are found in the nervous system and throughout the body. They are the targets of numerous widely used drugs, especially in the case of the most extensively studied βAR, β2AR, whose ligands are used for asthma and cardiovascular disease. βARs signal through Gαs G-proteins and via activation of adenylyl cyclase and cAMP-dependent protein kinase, but some alternative downstream pathways have also been proposed that could be important for understanding normal physiological functioning of βAR signaling and its disruption in disease. Using fluorescence-based Ca2+ flux assays combined with pharmacology and gene knock-out methods, we discovered a previously unrecognized endogenous pathway in HEK-293 cells whereby β2AR activation leads to robust Ca2+ mobilization from intracellular stores via activation of phospholipase C and opening of inositol trisphosphate (InsP3) receptors. This pathway did not involve cAMP, Gαs, or Gαi or the participation of the other members of the canonical β2AR signaling cascade and, therefore, constitutes a novel signaling mechanism for this receptor. This newly uncovered mechanism for Ca2+ mobilization by β2AR has broad implications for adrenergic signaling, cross-talk with other signaling pathways, and the effects of βAR-directed drugs.
Keywords:
G-protein-coupled receptor (GPCR); adrenergic receptor; calcium intracellular release; cell signaling; cyclic AMP (cAMP); β2-adrenergic receptor.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-Agonists / pharmacology
-
Boron Compounds / pharmacology
-
CRISPR-Cas Systems
-
Calcium Channel Blockers / pharmacology
-
Calcium Signaling* / drug effects
-
Endoplasmic Reticulum / drug effects
-
Endoplasmic Reticulum / enzymology
-
Endoplasmic Reticulum / metabolism*
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / pharmacology
-
Epinephrine / metabolism*
-
Estrenes / pharmacology
-
HEK293 Cells
-
Humans
-
Inositol 1,4,5-Trisphosphate Receptors / agonists*
-
Inositol 1,4,5-Trisphosphate Receptors / antagonists & inhibitors
-
Inositol 1,4,5-Trisphosphate Receptors / metabolism
-
Isoproterenol / pharmacology
-
Kinetics
-
Norepinephrine / metabolism*
-
Phosphoinositide Phospholipase C / antagonists & inhibitors
-
Phosphoinositide Phospholipase C / chemistry
-
Phosphoinositide Phospholipase C / metabolism*
-
Pyrrolidinones / pharmacology
-
Receptors, Adrenergic, beta-2 / chemistry
-
Receptors, Adrenergic, beta-2 / genetics
-
Receptors, Adrenergic, beta-2 / metabolism*
-
Recombinant Fusion Proteins / chemistry
-
Recombinant Fusion Proteins / metabolism
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases / antagonists & inhibitors
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases / chemistry
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
-
Thapsigargin / pharmacology
Substances
-
2-aminoethyl diphenylborinate
-
ADRB2 protein, human
-
Adrenergic beta-Agonists
-
Boron Compounds
-
Calcium Channel Blockers
-
Enzyme Inhibitors
-
Estrenes
-
ITPR1 protein, human
-
Inositol 1,4,5-Trisphosphate Receptors
-
Pyrrolidinones
-
Receptors, Adrenergic, beta-2
-
Recombinant Fusion Proteins
-
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
-
Thapsigargin
-
Phosphoinositide Phospholipase C
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases
-
Isoproterenol
-
Norepinephrine
-
Epinephrine